金天格胶囊作为腰椎间盘突出症附加治疗:开放标签随机对照试验
这项前瞻性单中心开放标签随机附加试验比较金天格胶囊联合常规治疗与单用常规治疗,主要终点为JOA评分,共随机64例。第2周、第8周及随访2周时JOA组间调整差异均有利于含金天格方案,第8周VAS、SF-12躯体和心理成分、麻木及腰椎活动度等多指标亦倾向获益,但开放标签、非安慰剂对照等设计局限因果推断。
要点
- 金天格胶囊联合常规治疗在改善JOA评分方面优于单用常规治疗。
- 第8周VAS、SF-12心理与躯体成分、腰椎肌肉弹性模量及活动度亦见组间差异。
- 开放标签、非安慰剂对照、单中心及样本量小限制结论的外推与因果归因。
核心结论
- 含金天格胶囊方案与常规治疗相比,在JOA评分及多项次要结局上显示更大改善。
研究设计与样本
- 前瞻性、单中心、开放标签随机附加试验,比较金天格胶囊联合常规治疗与单用常规治疗,共随机64例并纳入全部分配分析。
- 主要终点为JOA评分;次要终点包括VAS、SF-12躯体与心理成分评分、麻木、腰椎肌肉弹性模量及腰椎活动度。
主要发现
- 第2周JOA组间调整差异2.50分(95%CI 1.03-3.97;P<0.001),第8周2.73分(95%CI 1.21-4.26;P<0.001),随访2周1.79分(95%CI 0.27-3.32;P=0.021)。
- 第8周VAS调整差异-0.57(95%CI -0.89至-0.25),MCS 10.48(95%CI 9.58-11.39),PCS 4.02(95%CI 3.34-4.70)。
- 第8周腰椎肌肉弹性模量左侧-1.22(95%CI -2.37至-0.08)、右侧-1.53(95%CI -2.19至-0.86),活动度指标经多重性校正后亦有利于含金天格方案。
- 完成者分析显示效应方向相似。
关键数值与推荐
- JOA评分作为唯一主要终点,采用基线校正线性混合效应模型分析所有可用基线后观测。
- 第8周客观结局经多重插补后采用基线校正ANCOVA分析,并按Holm法控制多重性。
临床怎么用
- 对腰椎间盘突出症患者,在常规治疗基础上加用金天格胶囊可能有助于改善JOA评分及疼痛、躯体与心理功能等结局。
- 因开放标签、非安慰剂对照及单中心小样本,临床应用时应结合患者具体情况并关注证据不确定性。
局限性
- 开放标签、非安慰剂对照设计,评估者盲法未记录。
- 存在差异脱落(金天格组2例、对照组5例),且涉及多重性比较。
- 样本量小、单中心,限制因果推断与结果外推。
- 需进一步开展盲法、安慰剂对照、多中心试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lumbar disc herniation (LDH) is a prevalent and costly disorder. Evidence regarding the efficacy and safety of Jintiange (JTG) capsules as add-on therapy for LDH remains limited. METHODS: This prospective, single-center, open-label randomized add-on trial compared JTG capsules plus conventional therapy with conventional therapy alone. The Japanese Orthopaedic Association (JOA) score was the sole primary outcome; VAS, SF-12 physical and mental component scores (PCS/MCS), numbness, lumbar muscle elastic modulus, and lumbar range of motion (ROM) were secondary outcomes. All 64 randomized participants were included according to their assigned groups. JOA, VAS, PCS, and MCS were analyzed using baseline-adjusted linear mixed-effects models incorporating all available post-baseline observations. Week 8 objective outcomes were analyzed using baseline-adjusted ANCOVA after multiple imputation. Multiplicity across the specified Week 8 secondary outcomes was controlled using the Holm procedure, and complete-case analyses were performed as sensitivity analyses. RESULTS: Seven participants discontinued follow-up (2 JTG, 5 control). The adjusted between-group difference in JOA favored the JTG-containing regimen at Week 2 (2.50 points, 95% CI 1.03-3.97; P < 0.001), Week 8 (2.73, 95% CI 1.21-4.26; P < 0.001), and 2-week follow-up (1.79, 95% CI 0.27-3.32; P = 0.021). At Week 8, adjusted differences also favored the JTG-containing regimen for VAS (-0.57, 95% CI -0.89 to -0.25), MCS (10.48, 95% CI 9.58-11.39), PCS (4.02, 95% CI 3.34-4.70), lumbar muscle elastic modulus (left -1.22, 95% CI -2.37 to -0.08; right -1.53, 95% CI -2.19 to -0.86), and ROM measures after multiplicity adjustment. Complete-case analyses showed similar effect directions. CONCLUSION: The JTG-containing regimen was associated with greater improvement in JOA and several secondary outcomes than conventional therapy alone. However, the open-label, non-placebo-controlled design, undocumented assessor blinding, differential attrition, multiplicity, small sample size, and single-center setting limit causal attribution and generalizability. Further blinded placebo-controlled multicenter trials are warranted. CLINICAL TRIAL REGISTRATION: https://www.chictr.org.cn/, ChiCTR2300069735.
引用
- Liang L, Yang Y, Lv H, et al. Jintiange capsule as add-on therapy for lumbar disc herniation: an open-label randomized controlled trial. Front Pharmacol. 2026. PMID: 42922992. doi:10.3389/fphar.2026.1837527
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。